Prognostic Value of c-MYC Amplification by Fluorescence In Situ Hybridization in Cervical Cancer
K Lee, TJ Kim, A Lee, YJ Choi, KY Lee, JS Park, WS Lee. College of Medicine, the Catholic University, Seoul, Republic of Korea
Background: We examined c-MYC amplification in cervical cancer and analyzed its clinico-pathologic implication.
Design: Archival tissue from 163 patients with cervical cancer was prepared for tissue microarray (TMA) blocks. Immunohistochemical staining including bcl-2 and Ki-67 was performed and c-MYC gene amplification was determined by the dual-probe fluorescence in situ hybridization using a centromere-specific probe for choromosome 8 (8CEP) and a region-specific probe for c-MYC (Vysis® LSI® MYC (8q24) SpectrumTM Probe, Abbott/Vysis).
Results: We identified 6.7% (11/163) c-MYC amplification in cervical cancer, of which comprises 8 sqamous cell carcinomas, 2 adenocarcinomas and 1 adenosquamous cell carcinoma. c-MYC amplification was not associated with age, tumor depth of invasion, lymph node metastasis, histologic type and histologic differentiation but was significantly associated with higher mitotic count (p=0.022) and adversely associated with bcl-2 expression (p=0.022). bcl-2 expression was significantly associated with higher proliferation index (ki67≥51%)(p=0.039). Univariate survival analysis revealed that MYC amplification was significantly associated with worse recurrent free survival (p=0.011) and worse overall survival (p=0.037). Multivariate survival analyses using Cox-regression model revealed that c-MYC amplification and high stage were independantly associated with worse recurrence-free survival (p=0.042 and p=0.001) and that high stage was independently associated with worse tumor specific overall survival (p=0.001).
Conclusions: c-MYC amplification correlates with worse recurrence free survival and is independent prognostic factor in cervical cancer.
Category: Gynecologic & Obstetrics
Tuesday, March 23, 2010 9:30 AM
Poster Session III # 189, Tuesday Morning